Evidence map›Paper›PMID 34534000›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

May Different Treatment Volumes and Technical Approaches Have an Impact on Second Malignancies Risk?

Giulio Francolini, Lucia Pia Ciccone, Vanessa Di Cataldo, Beatrice Detti, Gabriele Simontacchi, Mauro Loi, Monica Mangoni, Isacco Desideri, Icro Meattini, Lorenzo Livi

Abstract readLetterComment

PubMed Publisher

In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

Commented on by
Reply to G. Francolini et al.2021
Comment on
Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial.2021

5 · Who and what money

Authors and funding

10 authors.

Giulio FrancoliniGiulio Francolini, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Lucia Pia Ciccone, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Vanessa Di Cataldo, MD, Cyberknife Center, Istituto Fiorentino di Cura ed Assistenza (IFCA), University of Florence, Florence, Italy; Beatrice Detti, MD, Gabriele Simontacchi, MD, and Mauro Loi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Monica Mangoni, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Isacco Desideri, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; and Icro Meattini, MD, and Lorenzo Livi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy.ORCID 0000-0002-1784-7203

Lucia Pia CicconeGiulio Francolini, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Lucia Pia Ciccone, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Vanessa Di Cataldo, MD, Cyberknife Center, Istituto Fiorentino di Cura ed Assistenza (IFCA), University of Florence, Florence, Italy; Beatrice Detti, MD, Gabriele Simontacchi, MD, and Mauro Loi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Monica Mangoni, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Isacco Desideri, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; and Icro Meattini, MD, and Lorenzo Livi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy.

Vanessa Di CataldoGiulio Francolini, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Lucia Pia Ciccone, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Vanessa Di Cataldo, MD, Cyberknife Center, Istituto Fiorentino di Cura ed Assistenza (IFCA), University of Florence, Florence, Italy; Beatrice Detti, MD, Gabriele Simontacchi, MD, and Mauro Loi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Monica Mangoni, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Isacco Desideri, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; and Icro Meattini, MD, and Lorenzo Livi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy.ORCID 0000-0003-3451-415X

Beatrice DettiGiulio Francolini, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Lucia Pia Ciccone, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Vanessa Di Cataldo, MD, Cyberknife Center, Istituto Fiorentino di Cura ed Assistenza (IFCA), University of Florence, Florence, Italy; Beatrice Detti, MD, Gabriele Simontacchi, MD, and Mauro Loi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Monica Mangoni, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Isacco Desideri, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; and Icro Meattini, MD, and Lorenzo Livi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy.

Gabriele SimontacchiGiulio Francolini, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Lucia Pia Ciccone, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Vanessa Di Cataldo, MD, Cyberknife Center, Istituto Fiorentino di Cura ed Assistenza (IFCA), University of Florence, Florence, Italy; Beatrice Detti, MD, Gabriele Simontacchi, MD, and Mauro Loi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Monica Mangoni, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Isacco Desideri, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; and Icro Meattini, MD, and Lorenzo Livi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy.ORCID 0000-0002-4005-6637

Mauro LoiGiulio Francolini, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Lucia Pia Ciccone, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Vanessa Di Cataldo, MD, Cyberknife Center, Istituto Fiorentino di Cura ed Assistenza (IFCA), University of Florence, Florence, Italy; Beatrice Detti, MD, Gabriele Simontacchi, MD, and Mauro Loi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Monica Mangoni, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Isacco Desideri, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; and Icro Meattini, MD, and Lorenzo Livi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy.

Monica MangoniGiulio Francolini, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Lucia Pia Ciccone, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Vanessa Di Cataldo, MD, Cyberknife Center, Istituto Fiorentino di Cura ed Assistenza (IFCA), University of Florence, Florence, Italy; Beatrice Detti, MD, Gabriele Simontacchi, MD, and Mauro Loi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Monica Mangoni, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Isacco Desideri, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; and Icro Meattini, MD, and Lorenzo Livi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy.ORCID 0000-0002-3422-6812

Isacco DesideriGiulio Francolini, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Lucia Pia Ciccone, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Vanessa Di Cataldo, MD, Cyberknife Center, Istituto Fiorentino di Cura ed Assistenza (IFCA), University of Florence, Florence, Italy; Beatrice Detti, MD, Gabriele Simontacchi, MD, and Mauro Loi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Monica Mangoni, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Isacco Desideri, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; and Icro Meattini, MD, and Lorenzo Livi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy.ORCID 0000-0002-9880-8387

Icro MeattiniGiulio Francolini, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Lucia Pia Ciccone, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Vanessa Di Cataldo, MD, Cyberknife Center, Istituto Fiorentino di Cura ed Assistenza (IFCA), University of Florence, Florence, Italy; Beatrice Detti, MD, Gabriele Simontacchi, MD, and Mauro Loi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Monica Mangoni, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Isacco Desideri, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; and Icro Meattini, MD, and Lorenzo Livi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy.ORCID 0000-0002-1861-2895

Lorenzo LiviGiulio Francolini, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Lucia Pia Ciccone, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Vanessa Di Cataldo, MD, Cyberknife Center, Istituto Fiorentino di Cura ed Assistenza (IFCA), University of Florence, Florence, Italy; Beatrice Detti, MD, Gabriele Simontacchi, MD, and Mauro Loi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy; Monica Mangoni, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; Isacco Desideri, MD, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy; and Icro Meattini, MD, and Lorenzo Livi, MD, Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy, Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Neoplasms, Second PrimaryHumans

Identifiers

PMID34534000

DOI10.1200/JCO.21.01790

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.